Abivax Shares Surge 3.9% at Midday After a 1,241% Increase Over the Year
Abivax shares rose by 3.9% this Tuesday at midday, reaching 98.60 euros, after closing at 94.90 euros the previous day. This rebound occurs in a favorable European context, with the CAC 40 up by 2.16% during the session. The French biotech, which has shown an exceptional annual performance of over 1,241%, is approaching a key deadline with the scheduled release of its 2025 annual results on March 23.
Short-Term Selling Pressure and Technical Rebound
Abivax's stock price has been trading below its 20-day and 50-day moving averages, at 103.56 euros and 103.81 euros respectively, indicating persistent short-term selling pressure. The 6.1% decline over three months highlights a consolidation phase following the spectacular surge over the past twelve months. Today's rebound is supported by the support level identified at 93.70 euros, which the stock approached during the last close. The Relative Strength Index (RSI), which measures overbought or oversold conditions, is at 30, on the border of the oversold zone. This technical level, often interpreted as a signal of short-term bearish excess, may explain the renewed interest observed this Tuesday. The most relevant resistance is at 112.40 euros, about 14% above the current price, a threshold that needs to be crossed to invalidate the recent corrective trend.
Focus on Upcoming 2025 Annual Results
Attention is now turning to the upcoming release of Abivax's 2025 annual results, scheduled for March 23. This date is a major event for the biopharmaceutical company, which is developing obefazimod for chronic inflammatory bowel diseases. The annual financial statements will provide an assessment of cash consumption and financial visibility, two crucial parameters for a biotech in the clinical development phase. The financial calendar then schedules the announcement of the first quarter 2026 results on June 1, followed by the half-year results on September 14. In European markets, this Tuesday's session unfolds in a general recovery atmosphere: the DAX is up 2.22% during the session, while the FTSE 100 is up 1.67%. In Asia, the Nikkei 225 closed up 2.88%. However, the VIX, a volatility barometer, was at 29.49 points in its last reading on March 6, indicating persistent tensions in global markets. Abivax, with a negative beta of -0.19, indicating a low correlation with major indices, maintains an atypical profile within the Parisian stock market.
